Clinical Biological and Pharmacological Factors Influencing Stroke Outcome "biostroke"


Phase N/A Results N/A

Trial Description

In a previous suty, we have demonstrated that prior transient ischemic attack, treatment lipid-lowering drug or physical activity are associated to a better outcome of stroke. The aim of the study is to understand the mechanisms of this preventive neuroprotection by establishing link between biomarkers and preventive and neuroprotective measures.To answer to the question, we conduct a cohort study of stroke patients.

Detailed Description

In the cohort, the severity of stroke (NIHSS) will be correlated with :
- clinical factors,
- pharmacological factors,
- biological factors (inflammatory markers, hemostasis...)


Trial Design

  • Observation: Cohort
  • Perspective: Prospective
  • Sampling: Probability Sample

Trial Population

Cohort of stroke patient


Type Measure Time Frame Safety Issue
Primary severity of stroke measured by NIH severity score inclusion, day7, month3, year3 No
Secondary clinical, pharmacological and biological (metabolic, inflammation, hemostasis...) cognitive status inclusion and year3 No

Biospecimen Retention:Samples Without DNA - whole blood and serum